Denali Therapeutics Inc.

19 clinical trials · Sponsor

Record	Firm	Date
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease (NCT07758595)	Denali Therapeutics Inc.	2026-08-01
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease (NCT07354724)	Denali Therapeutics Inc.	2026-05-12
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease (NCT07328451)	Denali Therapeutics Inc.	2026-01-30
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) (NCT06602193)	Denali Therapeutics Inc.	2024-10-24
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants (NCT06281158)	Denali Therapeutics Inc.	2024-03-01
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A) (NCT06181136)	Denali Therapeutics Inc.	2023-12-07
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 (NCT06075537)	Denali Therapeutics Inc.	2023-09-20
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) (NCT05371613)	Denali Therapeutics Inc.	2022-07-21
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants (NCT05450549)	Denali Therapeutics Inc.	2022-07-14
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) (NCT05262023)	Denali Therapeutics Inc.	2022-02-01
A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers (NCT04581772)	Denali Therapeutics Inc.	2020-12-23
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome (NCT04251026)	Denali Therapeutics Inc.	2020-07-16
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers (NCT04268784)	Denali Therapeutics Inc.	2020-02-20
A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome (NCT04007536)	Denali Therapeutics Inc.	2019-10-23
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease (NCT03757325)	Denali Therapeutics Inc.	2019-02-13
Study to Evaluate DNL201 in Subjects With Parkinson's Disease (NCT03710707)	Denali Therapeutics Inc.	2018-12-04
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers (NCT04557800)	Denali Therapeutics Inc.	2017-11-16

Track Denali Therapeutics Inc. automatically

Every clearance here is in the API, with alerts when new ones post.